SNN

Smith & Nephew
NYSE

Real-time Quotes | Nasdaq Last Sale

37.68
-0.04
-0.11%
After Hours: 37.68 0 0.00% 16:00 09/23 EDT
OPEN
38.34
PREV CLOSE
37.72
HIGH
38.48
LOW
37.53
VOLUME
242.04K
TURNOVER
--
52 WEEK HIGH
52.26
52 WEEK LOW
26.07
MARKET CAP
16.48B
P/E (TTM)
42.20
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Smith+Nephew's T.I.M.E. CDST launch judged Most Innovative at the 2020 Gartner Communications Awards
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today welcomes the announcement that its campaign to develop and promote the T.I.M.E. clinical decision support tool (CDST)1 was awarded Most Innovative in the category Excellence in Reputation & Thought Leadership at the 2020 Gartner
PR Newswire · 09/16 13:00
Smith+Nephew teams up with Avail Medsystems to help deliver remote procedural support, observation and clinical education to customers
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it has teamed up with Avail Medsystems (Palo Alto, CA) to provide remote, real-time collaboration services to its customers, directly in the OR. Smith+Nephew is the first Orthopaedics company to work with the Avail
PR Newswire · 09/15 13:00
What Does Smith & Nephew's Debt Look Like?
Shares of Smith & Nephew (NYSE: SNN) moved lower by 3.44% in the past three months. Before having a look at the importance of debt, let us look at how much debt Smith & Nephew has.Smith & Nephew's Debt According to the Smith & Nephew's most recent balance sheet as reported on March 4, 2016, total
Benzinga · 09/09 13:37
Smith+Nephew launches HEALICOIL KNOTLESS Suture Anchor; redefines healing potential for rotator cuff repair
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces the launch of the HEALICOIL KNOTLESS Suture Anchor, expanding its revolutionary line of Advanced Healing Solutions for rotator cuff repair. This portfolio includes the innovative REGENETEN™ Bioinductive Implant and novel
PR Newswire · 09/09 13:00
Smith+Nephew Launches HEALICOIL KNOTLESS Suture Anchor, Which Co Says 'Redefines Healing Potential For Rotator Cuff Repair'
Smith+Nephew launches HEALICOIL™ KNOTLESS Suture Anchor; redefines healing potential for rotator cuff repair LONDON, Sept. 9,2020 /PRNewswire/ --Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology
Benzinga · 09/09 12:30
Smith+Nephew's REDAPT System for revision total hip arthroplasty to be launched in China
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announced it has received approval from the National Medical Products Administration (NMPA) in China to introduce its REDAPT System for revision total hip arthroplasty (rTHA). The REDAPT System's acetabular components are
PR Newswire · 09/08 01:00
Smith+Nephew launches Novostitch Pro Meniscal Repair System in Europe
Smith & Nephew (SNN) announces the launch of its NOVOSTITCH PRO Meniscal Repair System in Europe after successfully receiving CE mark certification.This new system expands meniscal repair options to around 600,000 European
Seekingalpha · 09/02 10:13
Smith+Nephew launches NOVOSTITCH PRO Meniscal Repair System in Europe
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its NOVOSTITCH PRO Meniscal Repair System in Europe after successfully receiving CE mark certification. The NOVOSTITCH PRO Meniscal Repair System expands meniscal repair options to around 600,0001 European patients annually where the only previous option was removal.
PR Newswire · 09/02 08:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SNN. Analyze the recent business situations of Smith & Nephew through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SNN stock price target is 45.30 with a high estimate of 50.00 and a low estimate of 37.90.
EPS
Institutional Holdings
Institutions: 250
Institutional Holdings: 39.40M
% Owned: 9.00%
Shares Outstanding: 437.83M
TypeInstitutionsShares
Increased
81
1.91M
New
35
1.58M
Decreased
77
2.48M
Sold Out
34
540.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.43%
Healthcare Equipment & Supplies
-1.48%
Key Executives
Non-Executive Chairman/Independent Director
Roberto Quarta
Chief Executive Officer/Executive Director
Roland Diggelmann
Chief Financial Officer/Executive Director
Anne-Francoise Nesmes
Chief Financial Officer
Ian Melling
Corporate Executive
Brad Cannon
Corporate Executive
Myra Eskes
Corporate Executive
Simon Fraser
Corporate Executive
Mark Gladwell
Corporate Executive
Skip Kiil
Corporate Executive
Vasant Padmanabhan
Chief Human Resource Officer
Elga Lohler
Other
Catheryn O'Rourke
Chief Compliance Officer
Cathy O'Rourke
Other
Phil Cowdy
Other
Melissa Guerdan
Secretary
Susan Swabey
Non-Executive Director
Rick Medlock
Non-Executive Director
Bob White
Non-Executive Independent Director
Vinita Bali
Non-Executive Independent Director
Virginia Bottomley
Non-Executive Independent Director
Erik Engstrom
Non-Executive Independent Director
Robin Freestone
Non-Executive Independent Director
Marc Owen
Non-Executive Independent Director
Angie Risley
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
07/29/2020
Dividend USD 0.278
10/01/2020
--
Dividend USD 0.452
04/02/2020
--
Dividend USD 0.278
10/03/2019
--
Dividend USD 0.43
04/04/2019
--
Dividend USD 0.27
10/04/2018
02/08/2018
Dividend USD 0.444
04/05/2018
08/28/2017
Dividend USD 0.236
10/05/2017
02/27/2017
Dividend USD 0.37
03/29/2017
09/01/2016
Dividend USD 0.236
10/05/2016
02/08/2016
Dividend USD 0.37
04/20/2016
08/31/2015
Dividend USD 0.226
10/07/2015
04/17/2015
Dividend USD 0.372
04/15/2015
10/14/2014
Dividend USD 0.22
10/22/2014
02/19/2014
Dividend USD 0.83
04/17/2014
08/27/2013
Dividend USD 0.51
10/09/2013
03/08/2013
Dividend USD 0.79
04/17/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SNN
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Smith & Nephew plc (ADR) stock information, including NYSE:SNN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNN stock methods without spending real money on the virtual paper trading platform.